Cargando…
Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs
The current agents used for renal cell carcinoma (RCC) only exhibit the moderate response rate among patients. Development of drug resistance eventually fuels the need of either more potent drugs or new drugs to target the resistant pathways. Oridonin is a diterpenoid isolated from the Chinese medic...
Autores principales: | Zhou, Jiancheng, Yun, Eun-Jin, Chen, Wei, Ding, Ye, Wu, Kaijie, Wang, Bin, Ding, Chunyong, Hernandez, Elizabeth, Santoyo, John, Pong, Rey-Chen, Chen, Haiying, He, Dalin, Zhou, Jia, Hsieh, Jer-Tsong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386527/ https://www.ncbi.nlm.nih.gov/pubmed/28333136 http://dx.doi.org/10.1038/cddis.2017.121 |
Ejemplares similares
-
Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues
por: Chen, Wei, et al.
Publicado: (2016) -
Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection
por: Xu, Jimin, et al.
Publicado: (2018) -
The roles and mechanism of IFIT5 in bladder cancer epithelial–mesenchymal transition and progression
por: Huang, Jun, et al.
Publicado: (2019) -
The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes
por: Yun, Eun-Jin, et al.
Publicado: (2017) -
Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus
por: Zhang, Tingting, et al.
Publicado: (2015)